Effect of megestrol acetate on endometrial atypical hyperplasia and its influence on pregnancy outcome

Objective To analyze the clinical effect of megestrol acetate in the treatment of endometrial atypical hyperplasia (EAH) and the pregnancy outcome of patients. Methods Ninety-three patients with EAH who were treated at the First Affiliated Hospital of Zhengzhou University from January 2011 to January 2017 were retrospectively analyzed. Of the 93 patients with EAH, 45 cases were mild, 28 cases were moderate, and 20 cases were severe. During the treatment, hysteroscopy and diagnosis were performed every 3 months. After 2 years of follow-up, the clinical efficacy and pregnancy status of patients with fertility requirements were evaluated, and the factors related to pregnancy were analyzed. Results After treatment, 85 of 93 patients with EAH were effective, with a total effective rate of 91.3% (85/93). The total effective rate were higher in mild and moderate patients than that in severe cases (χ2=14.87, 4.38, P 0.05), but body mass index (BMI) and assisted reproductive technology were the influencing factors of pregnancy outcome (P<0.05). Conclusions The preventive treatment of endometrial atypical hyperplasia with megestrol acetate is reliable and the pregnancy rate is high. The use of assisted reproductive technology and BMI <30 kg/m2 can improve the pregnancy rate and pregnancy outcome. Key words: Endometrial atypical hyperplasia; Megestrol acetate; Assisted reproduction